Scarica l'app Stockscreener
1.27
1.60%
0.02
Dopo l'orario di chiusura:
1.28
0.01
+0.79%
Precedente Chiudi:
$1.25
Aprire:
$1.25
Volume 24 ore:
1.23M
Relative Volume:
1.33
Capitalizzazione di mercato:
$155.37M
Reddito:
$34.16M
Utile/perdita netta:
$-50.62M
Rapporto P/E:
-2.50
EPS:
-0.508
Flusso di cassa netto:
$703.00K
1 W Prestazione:
-7.97%
1M Prestazione:
-31.35%
6M Prestazione:
-67.52%
1 anno Prestazione:
-71.65%
Intervallo 1D:
$1.22
$1.28
Intervallo di 1 settimana:
$1.22
$1.414
Portata 52W:
$1.22
$4.96
Omniab Inc Stock (OABI) Company Profile
Nome
Omniab Inc
Settore
Industria
Telefono
510-250-7800
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta OABI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
1.27 | 168.82M | 34.16M | -50.62M | 703.00K | -0.508 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-21 | Iniziato | The Benchmark Company | Buy |
| 2023-04-13 | Iniziato | Craig Hallum | Buy |
| 2023-02-22 | Iniziato | Cowen | Outperform |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-11-29 | Iniziato | SVB Leerink | Outperform |
| 2022-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Omniab Inc Borsa (OABI) Ultime notizie
OABI stock touches 52-week low at $1.25 amid market challenges - Investing.com Australia
OABI stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
Northern Trust Corp Acquires 45,169 Shares of OmniAb, Inc. (NASDAQ:OABI) - Defense World
Deutsche Bank AG Increases Stake in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb’s SWOT analysis: antibody discovery firm’s stock faces growth opportunities amid market challenges - Investing.com Canada
OmniAb Inc (NASDAQ: OABI) Could Pass $4 In One Year Stock Forecast - Stocksregister
Insider Spends US$94k Buying More Shares In OmniAb - simplywall.st
Chairman of OmniAb Picks Up 3.0% More Stock - Yahoo Finance
51,159 Shares in OmniAb, Inc. (NASDAQ:OABI) Purchased by Balyasny Asset Management L.P. - Defense World
Price T Rowe Associates Inc. MD Has $136,000 Stock Position in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Leerink Partnrs Has Bullish Forecast for OmniAb Q2 Earnings - Defense World
Insider Buying: Jennifer Cochran Acquires 30,000 Shares of OmniA - GuruFocus
Director Makes Bold Move with Major OmniAb Stock Purchase - TipRanks
Insider Buying: Steven Love Acquires 25,000 Shares of OmniAb Inc (OABI) - GuruFocus
Director’s Bold Move: A Major Investment in OmniAb Stock - TipRanks
Insider Buying: John Higgins Acquires 65,000 Shares of OmniAb In - GuruFocus
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit - marketscreener.com
Hsbc Holdings PLC Makes New Investment in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb’s (OABI) “Buy” Rating Reaffirmed at Benchmark - Defense World
OmniAb: Too Much Risk, Not Enough Reward (NASDAQ:OABI) - Seeking Alpha
OmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call Transcript - MSN
OmniAb : May 2025 Corporate Overview - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88 - simplywall.st
Dimensional Fund Advisors LP Increases Position in OmniAb, Inc. (NASDAQ:OABI) - Defense World
RBC Capital Remains a Buy on OmniAb (OABI) - The Globe and Mail
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates - MSN
OmniAb’s Earnings Call: Growth Amid Challenges - TipRanks
OmniAb Introduces the xPloration® Partner Access Program - BioSpace
OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls By Investing.com - Investing.com South Africa
Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
OmniAb Introduces the xPloration(R) Partner Access Program - marketscreener.com
OmniAb Reports Steady Growth in Q1 2025 - TipRanks
OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls - Investing.com Nigeria
OmniAb, Inc. (NASDAQ:OABI) Shares Acquired by Barclays PLC - Defense World
OmniAb Inc (OABI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Wells Fargo & Company MN Purchases 12,278 Shares of OmniAb, Inc. (NASDAQ:OABI) - Defense World
Earnings call transcript: OmniAb’s Q1 2025 shows revenue growth and cost control - Investing.com
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
OmniAb Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OmniAb Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
OmniAb to Participate in Two Investor Conferences in November - marketscreener.com
Ratio Revelations: OmniAb Inc (OABI)’s Financial Metrics in the Spotlight - DWinneX
Veraxa and OmniAb to develop bispecific ADC tumour programme - Yahoo Finance
OmniAb, Veraxa Biotech Partner on Solid Tumor Drug Discovery Program - marketscreener.com
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - The Manila Times
VERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid Tumors - Nasdaq
Omniab Inc Azioni (OABI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):